PharmaBoardroom

The FDA’s COVID-19 Shakeup

In a recent virtual town hall meeting hosted by BIO, two key leaders from the US FDA laid out how their organisation has adjusted in the wake of the…

Korean Corestem Targets US Market for Ground-Breaking ALS…

After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the…

Company Spotlight: Arctic Vision

Founded by a veteran industry team, Arctic Vision recently celebrated its first anniversary and touts itself as the first innovative…

BIO 2020: How COVID-19 Will Radically Alter Global Biomedical…

The BIO International Convention was held digitally in June 2020, bringing together over 7,000 participants from around the world. In an…

Menarini Makes Big US Oncology Move with Stemline Acquisition

Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of…

Eddy Wu – Founder & CEO, Arctic Vision, China

Dr Eddy Wu, founder and CEO of new Chinese ophthalmology biotech Arctic Vision outlines the specific unmet ophthalmology needs in the Chinese market,…

Yan Tan – CEO, Xbiome, China

Yan Tan, CEO of Xbiome, the first AI-based microbiome drug development company in China, outlines the rationale behind the firm’s founding, what…

2020: A Watershed Year for Chinese Biotech

2020 will certainly go down in history as a watershed year for the global community, as a new strain of coronavirus – later named SARS-CoV-19 –…

Key Challenges for Life Sciences & Healthcare in 2020:…

‘The Key Challenges: Life Sciences and Healthcare 2020’ is the latest report from Cornerstone International Group based on a global survey of…

Johnsee Lee – Chairman & CEO & Eric Yang –…

Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how…

“Medication Adherence” is a Lunatic Endeavour

John G. Singer outlines why a focus on patients' adherence to their medication is not necessarily useful in working to improve health outcomes and why…

Kyung Suk Kim – CEO, Corestem

Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea,…

Tagged with R